Analysis of the efficacy of tirofiban in the treatment of transient ischemic attack with high risk of recurrence
10.19845/j.cnki.zfysjjbzz.2021.0131
- VernacularTitle:替罗非班治疗高复发风险短暂性脑缺血发作疗效分析
- Author:
Chunli FU
1
;
Mengkun WANG
1
;
Junhai WANG
1
Author Information
1. National Pharmaceutical and Coal General Hospital Neurology,Datong 037000,China
- Publication Type:Journal Article
- Keywords:
Tirofiban;
Anti-platelet aggregation;
Transient ischemic attack
- From:
Journal of Apoplexy and Nervous Diseases
2021;38(6):488-491
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of tirofiban on transient ischemic attack with high risk of recurrence.Methods 156 patients with non-cardiogenic transient ischemic attack with ABCD2 score ≥ 4 points were hospitalized at the Department of Neurology,Sinopharm Tongmei General Hospital from Jan 2019 to Mar 2021.Eight patients were excluded due to incomplete data or drop-off from follow-up.The remaining 148 patients were randomly divided into two groups,78 in the observation group and 70 in the control group.The observation group was given tirofiban treatment (loading tirofiban via a micropump,and continuous intravenous pumping for 48 hours) and intensive lipid-lowering therapy.The control group was given intensive anti-platelet aggregation therapy with Aspirin enteric-coated tablets,hydroclopidogre and intensive lipid-lowering therapy.We made a comparative analysis between two groups about efficacy,safety and short-term stroke incidence.Results In the observation group,57 cases were cured,14 cases were effective,and 7 cases were ineffective;6 cases (7.69%) had a stroke (cerebral infarction) within 7 days,7 cases (8.97%) had a stroke within 30 days,and 7 cases (8.97%) had a stroke within 90 days.In the control group,39 cases were markedly effective,15 cases were effective,and 16 cases were ineffective;in the control group,13 cases (18.57%) had a stroke (cerebral infarction) within 7 days,15 cases (21.43%) had a stroke within 30 days,16 cases (22.86%) had a stroke within 90 days.No intracerebral hemorrhage occurred in either group within 90 days.The two groups had statistical significance in terms of effective treatment rate (P<0.05).However,there was no significant difference in the number of stroke cases between the observation group and the control group in the short-term 7 days,30 days,and 90 days (P>0.05).There was no significant difference in coagulation,platelet,liver and kidney function between the two groups after 48 hours of treatment (P>0.05).Conclusion For patients with transient ischemic attack at high risk of recurrence,tirofiban treatment can effectively control TIA attacks,but it cannot reduce the risk of stroke.
- Full text:2024072921502077458Analysis of the efficacy of tirofiban in the treatment of transient ischemic attack with high risk of recurrence.pdf
